Attachment 1 - Purchase Description.pdf

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

PURCHASE DESCRIPTION

1. Statement of Need and Purpose: The National Institute on Aging (NIA) requires seven

(7) multiplexed precision proteomics immunoassay panel and required bulk reagents used to run the testing and analysis for neurological disease biomarkers for an in-depth study of the protein changes with neurodegeneration and how dietary interventions may modulate them.

2. Background Information and Objective:

Chronic pain is one of the most pervasive and disabling health challenges worldwide, contributing to reduced quality of life, social isolation and cognitive decline. Despite its impact, we are still lacking objective biomarkers that can capture and track underlying physiopathological processes and predict treatment response. Moreover, despite taking multiple drugs, patients still report substantial disability. Dietary interventions represent a promising therapeutic approach by modulating neuroinflammation and glial activation which underlie chronic pain. Leveraging samples from a randomized clinical trial of fatty-acid dietary interventions in chronic pain patients, we aim to identify plasma and exosome-derived biomarkers that allow monitoring of treatment response, as well as identify novel therapeutic targets to guide precision medicine interventions in older adults living with chronic pain.

Neurodegenerative disease research is complicated by a high degree of clinical heterogeneity and the prevalence of co-pathologies. The identification of clinically relevant biomarkers for neurological disorders is critical in the development of better tools for diagnosis, disease progression, and prediction of therapeutic outcomes. NIA requires a brand name or equal NULISAseq Neuro 220 Panel to provide comprehensive coverage of the hallmarks of neurodegenerative disease with highly sensitive and specific multiplexed analysis of 220 biomarkers using only 25 μL of sample, providing researchers with an automated solution to dissect disease heterogeneity, uncover co-pathologies, and identify signatures of disease prognosis, progression, and therapeutic response in clinical cohorts.

3. Generic Name of Product: Multiplexed precision proteomics immunoassay panel for neurological disease biomarkers and bulk reagents required to run the testing and analysis.

4. Salient characteristics NIA requires the following brand name or equal items:

a. NULISAseq Neuro 220 Panel. Qty. 7

b. NULISA 10X Wash Buffer. Qty. 2

NIA requires a proteomics immunoassay panel for neurological disease biomarkers technology that meets the demand for ultra-high sensitivity, wide dynamic range, and high multiplexing with the following salient characteristics:

Unprecedented Sensitivity

• Attomolar level of detection (as low as 0.1 fg/mL)

• Quantification of low-abundance proteins not measurable by existing platforms

• Enabled by 4 levels of built-in assay specificity

• Signal-to-noise ratio improved by >10,000-fold via proprietary enhancement technology

Widest Dynamic Range

• Up to 12 logs of dynamic range

• Quantification across the full biological range of protein levels

• Accomplished in a single reaction without dilution

True High-Multiplexing

• Single target or multiplex capability

• 100s to 1,000s of targets quantified in a single reaction

• Broad sample type compatibility: plasma, serum, CSF, urine, and cell culture media

Specific Biomarkers for detection include:

Abeta38 (ab38), Abeta40 (ab40), Abeta42 (ab42), ACHE, AGRN, ANXA5, ApoA1, APOA2, APOE, APOE4, APOH (Apolipoprotein H/B2G1), AQP4, ARSA, ATXN2

(ATX2/SCA2/TNRC13), ATXN3 (ATX3/MJD/MJD1/SCA3), AXL (UFO), BACE1, BASP1,

BCAN (BEHAB/CSPG7), BD-pTau181, BD-pTau205, BD-pTau212, BD-pTau217, BD-pTau231, BD-tTau, BDNF, C1Q, CALB2, CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP- 1β), CCL5 (RANTES), CCL11 (Eotaxin), CCL13 (MCP-4), CCL17 (TARC), CCL18, CCL22 (MDC), CCL26 (Eotaxin-3), CD33, CD40LG, CD63, CGRP, CHI3L1 (YKL-40), CHIT1, CNDP1, CNTN2, CRH, CRP, CSF1R (CD115), CSF2 (GM-CSF), CST3, CST5, CTNNB1, CX3CL1 (Fractalkine), CXCL1 (GROα), CXCL8 (IL-8), CXCL10 (IP-10), CXCL13 (BCA-1), DDC, Dkk1, DLG4 (PSD-95), DNM1L (DRP1/DLP1), EDA2R, EFEMP1, EGFR, EIF4EBP1, eMTBR-Tau, ENO2, F2R, FABP3, FAM3B, FCGR2A (CD32A), FCGR2B (CD32B), FCN2, FGF2 (bFGF), FGF21, FGFBP1, FLT1 (VEGF R1), FOLR1, GAP43, GAS6, GBA1, GDF-15, GDI1, GDNF, GFAP, GLP1R, GOT1, GPNMB, GRN (Progranulin), GSDMD, GSDME, HBA1; HBA2 (HBα1; HBα2), HMOX1, HPGDS, HSPB1, HTT, ICAM1 (CD54), IFNG (IFN-γ), IGF1R, IGFBP7, IL-1B (IL1B), IL-2 (IL2), IL- 4, IL-5, IL-6, IL-6R (IL-6RA), IL-7, IL-9, IL-10, IL-12A|IL-12B (IL-12p70), IL-13, IL-15, IL-

16, IL-17A, IL-18, IL-33, ITGAV (CD51), KDR (VEGFR-2), KLK6, L1CAM, LDLR,

LGALS3, LRRK2, MAG, MDH1, MDK (Midkine), mHTT-exon1 (HTT), MME, MMP9, MMP10, MOG, MSLN, NCAM1, NEFH, NEFL (NfL), NELL1, NFKB1, NFKB2, NGF, NLRP3, NPTX1, NPTX2, NPTXR, NPY, NRGN, NT-ProBNP (NPPB), NTRK2, NTRK3, Oligo-SNCA (SNCAagg), PAFAH1B3 (PAFAHG), PARK7 (DJ-1), PARP1, PDGFC, PDGFRB, PDLIM5, PGF, PGK1 (PGK1), PLAUR, POSTN, PPBP (CXCL7), pPRKN-S65 (PRKN), PPY, pQ-ATXN3 (ATXN3/ATX3/MJD/MJD1/SCA3), pQ-HTT (HTT), pRab10- T73, pRab12-S106, pRab29-T71, PRDX5, PRDX6, PRKN (Parkin), PROS1, pS1292 LRRK2, PSEN1, PSME1, pSNCA-129 (SNCA), pTARDBP-S409, pTau181, pTau205, pTau212, pTau217, pTau231, PTN, PTPRS, Rab10, Rab12, RAB29, REST, RUVBL2, S100A12, S100B, SAA1, SerpinA3, SFRP1, SFTPD, SLIT2, SMOC1, SNAP25, SNCA, SNCB, SOD1, SPP1, SQSTM1, STMN2, STX4, TDP-43 (TARDBP), TEK (TIE-2), TIMP3, TNF (TNF-α), TNFSF14 (CD258), TREM-1 (sTREM1), TREM-2, tTau (totalTau), UBB, UCHL1, VCAM-1 (CD106), VEGF-A, VEGF-D, VGF, VSNL1 (VILIP), YWHAG, YWHAZ

Panels must be compatible with the ARGO HT System:

• All-in-one instrument with integrated qPCR system takes you from sample to data or to pooled NGS library

• Fully automated workflow with <30 min total hands-on time

• High throughput capacity processes up to 288 samples per run

• Rapid results in <6 hrs for single-plex assays and <15 hrs for multiplex NGS assays

• Integrated software and data analysis transforms data into biological insights and publication-ready results

ARGO HT Instrument Specifications Specification

Value

Width 1143 mm (45 in) Height 1016 mm (40 in) Depth 661 mm (26 in) Weight 250 kg (552 lbs.)

Operating Temperature 15°C – 24°C (59°F – 75°F) Relative Humidity 40 – 80%, non-condensing Altitude 2000 m (6560 ft) Power Supply Auto-ranging, 100–240 V~, 50–60 Hz Earth Grounded

Outlet Rated Current / Fuse 15A 500 Vac, 6.3×32mm (type 505 F15AH500V) Maximum Instantaneous Power 1500 watts Heat Energy 4470 BTU/hr

4. Quantity:

7x NULISAseq Neuro 220 Panel 2X NULISA 10X Wash Buffer

5. Delivery Date: Delivery shall be made within 30 days after receipt of Order. Delivery shall be made to the following:

National Institute on Aging (NIA) Ana Patricia Amorim Gomes 251 Bayview Boulevard

8C009 BRC

Baltimore, Maryland 21224 United States patricia.amorimgomes@nia.nih.gov